BGB-43395 trials for Breast cancer

All BGB-43395 trials · All Breast cancer trials

Phase breakdown

Recruiting trials studying BGB-43395 for Breast cancer

• BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
  NCT06756932 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
  NCT06120283 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 62 locations
• BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
  NCT07492641 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 108 locations

Common questions

How many trials study BGB-43395 for Breast cancer?

3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.